CEO Magazine Press Release
Art of Healing Cancer, one of the leading organizations focused on precision oncology to treat cancer patients, is raising awareness about the high cost of immunotherapy treatment in India by sharing important information on the subject. The organization aims to shed light on the financial burden patients and their families face, advocating for greater accessibility to this life-saving treatment option.
New Delhi, Delhi, India Business Wire India Art of Healing Cancer, one of the leading precision oncology setups in the country, is excited to present the latest findings on the science of metabolic therapy in treating cancer. This innovative approach alters cancer cells' metabolism to target and inhibit their growth, offering a promising alternative to traditional cancer treatments.
Art of Healing Cancer, a globally renowned Precision and integrative oncology institution located in Gurgaon, underscores the possible benefits of incorporating the anti-malarial drug, Artesunate, into cancer treatments. This insight could introduce novel approaches to enhance the effectiveness of traditional cancer therapies.
Sentinel Lymph Node Biopsy (SLNB) is a crucial diagnostic procedure that helps physicians identify and evaluate the first lymph node(s) affected by cancer, known as the sentinel lymph node(s). This assessment is crucial in determining whether cancer has spread beyond its primary site.
Art of Healing Cancer, a leading cancer care provider in India, is pleased to share information on the role of liquid biopsy in the management of cancer. This technique is revolutionising cancer care by providing a non-invasive and more accurate way of detecting cancer and monitoring its progression.
Cervical cancer is the fifth most common cancer among women globally according to World Health Organization (WHO). India accounts for one-fifth (1/5th ) of the global burden of the disease. Every year in India, approximately 1.23 lakh women are diagnosed with cervical cancer and around 67,000 die from the disease.
In 2020, the combined age-standardised rate for all cancers, excluding non-melanoma skin cancer, was 190 per 100,000, and men had a greater rate of developing cancer (206.9 per 100,000) than women (178.1 per 100,000). Unfortunately, this number has already been surpassed in the year 2022.